One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin.

Brown DB, Gonsalves CF, Yeo CJ, Witkiewicz AK, Carr BI
Oncol Rep. 2010 24 (3): 767-9

PMID: 20664985 · DOI:10.3892/or_00000919

While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.

MeSH Terms (16)

Antimetabolites, Antineoplastic Carcinoma, Pancreatic Ductal Cell Differentiation Chemoembolization, Therapeutic Cisplatin Deoxycytidine Humans Liver Neoplasms Male Middle Aged Pancreatectomy Pancreatic Neoplasms Positron-Emission Tomography Time Factors Tomography, X-Ray Computed Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: